R

Avita Medical
D

RCEL

12.950
USD
0.09
(0.70%)
Market Open
Volume
604
EPS
-3
Div Yield
-
P/E
-6
Market Cap
339,518,296
OverviewSignalsIdeasNews
Related Instruments
    A
    ADAP
    -0.00320
    (-0.54%)
    0.58680 USD
    A
    ADMP
    0
    (0%)
    0.000000 USD
    A
    ARDX
    0.25000
    (5.30%)
    4.96500 USD
    A
    ATHX
    0.00290
    (2.96%)
    0.10100 USD
    B
    BCRX
    -0.41500
    (-5.57%)
    7.03500 USD
    N
    NAOV
    -0.01870
    (-2.84%)
    0.63950 USD
    P
    PLRX
    -0.390
    (-3.04%)
    12.460 USD
    P
    PSTV
    -0.08000
    (-6.35%)
    1.18000 USD
    V
    VCEL
    -0.240
    (-0.46%)
    52.510 USD
    More
News

Title: Avita Medical

Sector: Healthcare
Industry: Medical Devices
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.